This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

InterMune Completes Divestiture Of Actimmune® (interferon Gamma-1b)

BRISBANE, Calif., June 20, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that on June 19, 2012, the company completed the previously announced sale of its rights to Actimmune® (interferon gamma-1b) to Vidara Therapeutics International Limited (Vidara).  Vidara is part of an international specialty pharmaceutical group of companies with operations in Ireland and the United States.

Gross proceeds from the sale totaled $55.0 million.  In addition, InterMune is eligible to receive a two-year royalty stream based on net sales of Actimmune, which is expected to contribute an aggregate amount of approximately $2-$4 million over the two-year period.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "We are pleased to complete the divestiture of Actimmune.  The cash infusion from this transaction combined with $377.2 million of existing cash and cash equivalents at the end of Q1 2012, and our new estimates for lower operating expenses in 2012, will provide additional financial flexibility as we launch Esbriet® (pirfenidone) in Europe and work to make the medicine available to idiopathic pulmonary fibrosis patients in the United States and in other countries."

Guidance for 2012 Expenses

The company today updated its forward-looking financial guidance for operating expenses in 2012, initially provided on January 5, 2012:

  • R&D expense: currently anticipated to be in a range of $90 to $105 million (previously $95 to $115 million).  The updated R&D expense range reflects anticipated timing of completion of enrollment in the ASCEND Phase 3 study, which is currently expected around the end of 2012, as well as a delay of investments in certain non-Esbriet R&D activities.
  • SG&A expense: currently anticipated to be in a range of $110 to $130 million (previously $120 to $145 million).  The updated SG&A expense range reflects the company's current expectations for the timing of the completion of pricing and reimbursement discussions for Esbriet in Europe.
  • Total Operating Expenses (R&D and SG&A): currently anticipated to be in a range of $200 to $235 million (previously $215 to $260 million). 

About Actimmune®

Actimmune is a synthesized version of interferon gamma, a naturally occurring protein believed to stimulate the immune system.  Actimmune is FDA approved for the treatment of two life-threatening, ultra-orphan, congenital diseases: chronic granulomatous disease and severe, malignant osteopetrosis.  The most common side effects are flu-like symptoms, including headache, fatigue, fever, chills and rash.  Physicians and patients can obtain additional prescribing information regarding Actimmune, including the product's safety profile, by visiting www.actimmune.com.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.  In pulmonology, the company is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved  for IPF anywhere in the world, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including, without limitation, the statements related to our expectations regarding the amount of royalties we may receive during the two-year period for sales of Actimmune, the uses of the capital from the divestiture of Actimmune for investing in the development and commercialization of Esbriet, our projections for anticipated operating expenses for 2012, and our expectation regarding the timing of full enrollment in the ASCEND study.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs